Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

36° Cloudy

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

536.21 +10.54 (+2.00%)

Streaming Delayed Price Updated: 10:04 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗

October 15, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗

September 29, 2025

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Via Benzinga

MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗

September 24, 2025

Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating.

Via Chartmill

MarketBeat Week in Review – 09/08 - 09/12 ↗

September 13, 2025

Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in

Via MarketBeat

Topics Economy

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts ↗

September 12, 2025

Via Benzinga

CoreWeave and Madrigal's Insider Trades Flash Bullish Signals ↗

September 10, 2025

Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.

Via MarketBeat

Topics Artificial Intelligence

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗

August 28, 2025

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.

Via Investor's Business Daily

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗

August 26, 2025

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.

Via Benzinga

Why Madrigal Pharmaceuticals Stock Is Soaring Today ↗

February 26, 2025

Via The Motley Fool

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

August 26, 2025

Via Benzinga

Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism

August 20, 2025

In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust...

Via MarketMinute

Topics Artificial Intelligence Economy

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma ↗

August 18, 2025

The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.

Via Investor's Business Daily

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease ↗

August 18, 2025

FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.

Via Benzinga

Billionaire Investor Buys Google And This Gold Miner Stock ↗

August 16, 2025

John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.

Via Benzinga

Madrigal (MDGL) Q2 Revenue Soars 1,313% ↗

August 05, 2025

Via The Motley Fool

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales ↗

August 05, 2025

Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.

Via Chartmill

European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug ↗

June 20, 2025

Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.

Via Benzinga

5 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2025

Via Benzinga

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗

May 13, 2025

Via The Motley Fool

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock ↗

May 11, 2025

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,...

Via Stocktwits

Topics Death

Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview ↗

April 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 25, 2025

Via Benzinga

Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday ↗

February 26, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis ↗

February 26, 2025

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: vctr@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

Sections

Services

Follow Us